Moreno, R.; Redondo, C.; Pérez-Davó, A.; Moreno, E.; Redondo, P. New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis. Children2019, 6, 17.
Moreno, R.; Redondo, C.; Pérez-Davó, A.; Moreno, E.; Redondo, P. New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis. Children 2019, 6, 17.
Moreno, R.; Redondo, C.; Pérez-Davó, A.; Moreno, E.; Redondo, P. New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis. Children2019, 6, 17.
Moreno, R.; Redondo, C.; Pérez-Davó, A.; Moreno, E.; Redondo, P. New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis. Children 2019, 6, 17.
Abstract
Atopic dermatitis (AD) is a chronic cutaneous inflammatory disorder, characterized by skin barrier disruption. Dermacare is a new cosmetic formulation which enhances moisturization, reinforces and repairs the skin barrier and prevents cutaneous microbiota imbalance. To demonstrate its safety and efficacy a prospective, open-label and multicenter study was carried out on patients diagnosed with mild to moderate AD. Transepidermal water loss (TEWL), clinical severity, Desquamation Index, Patient/Investigator Global Assessments, quality of life index and tolerance were assessed. Adverse events were recorded. Daily application of the new treatment was well tolerated, and adverse events were absent. After 14 days, TEWL showed a 36.7% significant decrease (p = 0.035). At the end of the 28-day Dermacare treatment, the Desquamation Index showed a reduction in 70% of patients; Eczema Area and Severity Index were reduced by 70.4% (p = 0.002); and skin irritation showed a significant reduction (p = 0.024). Likewise, Patient and Investigator Global Assessments reported a significant improvement in conditions and an overall global worsening when patients restarted their normal treatment. Parent’s Index of Quality of Life Index significantly increased by 36.4% (p < 0.05) with Dermacare. In conclusion, Dermacare’s regular use helped reduce the risk of relapse and extend the steroid-free treatment periods.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
